CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 1,270 shares at $27.67 ($35,143)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 51,145 shares at an average $28.11 ($1,437,585)
- 4 Planned sale PRESIDENT AND CEO sold 29,977 shares at an average $28.07 ($841,334)
- 4 Planned sale Director sold 10,420 shares at $28.17 ($293,557)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 10,229 shares at an average $27.54 ($281,664)
- 4 Planned sale PRESIDENT AND CEO sold 14,936 shares at an average $27.51 ($410,867)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 11,488 shares at an average $27.51 ($316,014)
- 4 Planned sale Director sold 2,825 shares at $27.51 ($77,704)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 527 shares at $27.54 ($14,512)
- 4 Planned sale PRESIDENT AND CEO sold 526 shares at $27.54 ($14,485)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 521 shares at $27.54 ($14,347)
- 4 Planned sale Director sold 518 shares at $27.54 ($14,264)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 6,250 shares at an average $24.61 ($153,829)
Page 16 of 40 · 798 filings